WallStSmart

Coca-Cola European Partners PLC (CCEP)vsNorthrop Grumman Corporation (NOC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Northrop Grumman Corporation generates 103% more annual revenue ($42.37B vs $20.90B). NOC leads profitability with a 10.8% profit margin vs 9.3%. CCEP appears more attractively valued with a PEG of 2.64. NOC earns a higher WallStSmart Score of 63/100 (C+).

CCEP

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 3.3Quality: 4.0
Piotroski: 3/9Altman Z: 1.55

NOC

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCEPSignificantly Overvalued (-64.8%)

Margin of Safety

-64.8%

Fair Value

$59.24

Current Price

$94.57

$35.33 premium

UndervaluedFair: $59.24Overvalued
NOCSignificantly Overvalued (-60.9%)

Margin of Safety

-60.9%

Fair Value

$421.87

Current Price

$549.52

$127.65 premium

UndervaluedFair: $421.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP3 strengths · Avg: 9.0/10
EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Return on EquityProfitability
22.9%9/10

Every $100 of equity generates 23 in profit

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

NOC4 strengths · Avg: 9.0/10
EPS GrowthGrowth
84.9%10/10

Earnings expanding 84.9% YoY

Market CapQuality
$78.44B9/10

Large-cap with strong market position

Return on EquityProfitability
28.5%9/10

Every $100 of equity generates 29 in profit

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

Areas to Watch

CCEP4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Debt/EquityHealth
1.503/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NOC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.

Bull Case : NOC

The strongest argument for NOC centers on EPS Growth, Market Cap, Return on Equity.

Bear Case : CCEP

The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : NOC

The primary concerns for NOC are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CCEP carries more volatility with a beta of 0.49 — expect wider price swings.

NOC is growing revenue faster at 4.4% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor BEVERAGES - NON-ALCOHOLIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NOC scores higher overall (63/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Visit Website →

Northrop Grumman Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Northrop Grumman Corporation (NYSE: NOC) is an American multinational aerospace and defense technology company.

Visit Website →

Want to dig deeper into these stocks?